Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wilder

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 28, 2003
Clinical implications of incorporating heterogeneity corrections in mantle field irradiationSteven M Kirsner, Rajat J Kudchadker, Karl L Prado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2001
Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatmentC E Pelloski, R B Wilder, C S Ha, et al.
The Journal of Urology|November 11, 2005
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictorsJoseph P Brooks, Paul S Albert, Richard B Wilder, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 2, 2021
Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancerCasey Liveringhouse, Austin Sim, Kosj Yamoah, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2009
A prospective study of intrafraction prostate motion in the prone vs. supine positionRichard B Wilder, Lucy Chittenden, Albert V Mesa, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|July 23, 2015
Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumesGeorge Yang, Tobin J Strom, Richard B Wilder, et al.
Cancer|September 26, 2001
Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphomaC S Ha, S L Tucker, A I Blanco, et al.
Cancer Journal (Sudbury, Mass.)|March 6, 2004
Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21)Chul S Ha, Ming-Sheng Lee, Peter McLaughlin, et al.
Patient Education and Counseling|October 1, 1994
A comparison of education methods and their impact on behavioral change in patients with hyperlipidemiaA S Dobs, R B Masters, L Rajaram, et al.
Cancer|June 20, 2001
Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphomaR B Wilder, M A Rodriguez, C S Ha, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
International Journal of Radiation Oncology, Biology, Physics|February 28, 2003
Clinical implications of incorporating heterogeneity corrections in mantle field irradiationSteven M Kirsner, Rajat J Kudchadker, Karl L Prado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2001
Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatmentC E Pelloski, R B Wilder, C S Ha, et al.
The Journal of Urology|November 11, 2005
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictorsJoseph P Brooks, Paul S Albert, Richard B Wilder, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 2, 2021
Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancerCasey Liveringhouse, Austin Sim, Kosj Yamoah, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2009
A prospective study of intrafraction prostate motion in the prone vs. supine positionRichard B Wilder, Lucy Chittenden, Albert V Mesa, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|July 23, 2015
Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumesGeorge Yang, Tobin J Strom, Richard B Wilder, et al.
Cancer|September 26, 2001
Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphomaC S Ha, S L Tucker, A I Blanco, et al.
Cancer Journal (Sudbury, Mass.)|March 6, 2004
Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21)Chul S Ha, Ming-Sheng Lee, Peter McLaughlin, et al.
Patient Education and Counseling|October 1, 1994
A comparison of education methods and their impact on behavioral change in patients with hyperlipidemiaA S Dobs, R B Masters, L Rajaram, et al.
Cancer|June 20, 2001
Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphomaR B Wilder, M A Rodriguez, C S Ha, et al.
Pageof 11